Doug Drysdale is the Chief Executive Officer of Alvogen. Recognized in 2011 as an Emerging Pharma Leader by Pharmaceutical Executive magazine, Mr. Drysdale has been the driving force behind more than 100 pharmaceutical and biotech transactions. For almost 20 years, he has applied his leadership skills and strategic vision to build and grow complex, multi-region businesses. Citing his global pharmaceutical leadership, Mr. Drysdale was honored in 2011 by the International Business Awards as a distinguished executive within pharmaceuticals.

Mr. Drysdale joined the company in 2008, after three years with the generic pharmaceuticals company Actavis Group, as VP of Mergers & Acquisitions. Previously he served in a VP capacity for the multinational Alpharma, where he was responsible for global business development. His entrepreneurial character was firmly formed early on, as co-founder of Alkensa, Inc., a CNS development company, where Mr. Drysdale served as Executive VP of Corporate Development.

An ardent student of the biological sciences as well as the pharmaceutical industry throughout his life, Mr. Drysdale earned a degree in Microbial and Molecular Biology from the University of East Anglia, UK.

Dale Martin provides Alvogen with more than 30 years of generic pharmaceuticals experience. Mr. Martin began his career with Mylan Pharmaceuticals in 1977 where he successfully contributed for 25 years to the company’s growth and expansion. His valuable capabilities for corporate development were established during his tenure with Abrika Pharmaceuticals, where he was the VP of Corporate Development, and then later at Actavis Inc., where Mr. Martin served as a Managing Director.

Mr. Martin was the Chairman of the National Pharmaceutical Association (NPA) and was a driving force behind the merger of all three generic trade associations into the Generic Pharmaceutical Association (GPHA). He graduated with a bachelor’s degree and a M.B.A. from West Virginia University.

Mr. Price is an experienced pharmaceutical business development executive who has led negotiations for more than 30 pharmaceutical business transactions involving over 100 molecules.

Most recently, Mr. Price was the CEO of ATR Biopharma, LLC, a consultancy specializing in technology licensing, alliance management, R&D strategy and product selection. Mr. Price previously served as Senior Vice President of Business Development for KV Pharmaceuticals. In that role, he structured numerous licensing agreements with a broad range of partners.

Prior to joining KV, Mr. Price held executive leadership positions with Ivax Corporation, Halsey Pharmaceuticals (now Acura), and Barr Laboratories. He holds an MBA and Bachelor of Science in Engineering from the University of Michigan.

William Hill brings over 20 years of brand and generic pharmaceuticals experience that includes multiple therapeutic areas and all classes of trade. Mr. Hill comes to Alvogen from Dr. Reddy’s Laboratories, where he led North American sales and commercial operations for the past three years. He was promoted to VP Sales after a successful tenure in National Accounts, highlighted by several Paragraph 4 product launches and Dr. Reddy’s entry into the top ten generic company status.

Prior to Dr. Reddy’s, Mr. Hill served in sales and management roles URL, Dey, Warner Chilcott, Endo and Sandoz.

Andrea Johnson has more than 20 years’ experience in both generic and branded pharmaceuticals. Her knowledge and experience in Customer Focus, Operational Effectiveness, Teambuilding and Process Improvements (Kaizen and Lean Six Sigma) allows her to effectively lead and manage Alvogen’s customer service, credit & collections and contracting & pricing operations.

Prior to joining Alvogen, Mrs. Johnson was the Senior Director of Pricing & Contracts and Financial Sales Operations at Actavis Inc., where she was able to successfully lead significant operational improvements resulting in millions of dollars in savings. Mrs. Johnson has held roles of increasing responsibility throughout her career including successful positions at Johnson & Johnson Healthcare Systems, Pfizer and Alpharma.

Jasmine Shah is the Vice President of Research & Development and Regulatory Affairs for Alvogen. He joined the Company in 2009, after spending four years with the generic pharmaceuticals company Actavis Group, as VP of Regulatory and Medical Affairs in the U.S. Previously he served in a VP capacity for Amide Pharmaceuticals, where he was responsible for Regulatory and Compliance.

Shah successfully has led more than 200 ANDA submissions. For over 20 years, he has applied his skills and knowledge to build and grow pharmaceutical businesses. A licensed pharmacist by profession, Shah holds an undergraduate degree in Pharmacy from University of Poona, India and a Masters in Industrial Pharmacy from Long Island University, U.S.

Lisa Graver drives the execution of critical business projects and processes throughout the Alvogen Americas business. Ms. Graver leads Business Development and Licensing activities, R&D and Regulatory Affairs Strategies, selection of candidates for Product Development, and directs all US Intellectual Property strategy and litigation. Ms. Graver applies more than 15 years experience representing pharmaceutical companies in patent litigation and counseling. Her achievements include successful results while in private practice, formerly with Kirkland & Ellis, and then as the in-house counsel for generic pharmaceutical companies Alpharma and Actavis.

Ms. Graver holds a juris doctorate, cum laude, from Case Western Reserve University School of Law. She earned her undergraduate degree, with honors, in biology and biological anthropology from Lakehead University.

Delivering more than 30 years of brand and generic pharmaceuticals supply chain management experience, Steve Kondracki leads Alvogen strategic planning for product supply and distribution. Throughout his career, Mr. Kondracki, a certified Lean Six Sigma Black Belt, has successfully directed all aspects of pharmaceutical supply chain management for both regional and international operations.

Prior to joining Alvogen, Mr. Kondracki led supply chain operations for companies including Alpharma, Barr and Wockhardt. He earned an honors degree in Management Science from Rutgers University.

Dr. Mayank Joshi, Vice President of Research and Development, leads both internal and external scientific development teams responsible for ensuring successful execution of product development, product transfers, scale-up, process engineering, facility and equipment qualification and all validation tasks to support revenue and profitability growth for Alvogen's US organization.

He is also driving the development of first to file ANDAs in the development pipeline, and conducting technical due diligence for potential third party partners identified by business development. Dr Joshi has extensive experience of about 20 years in the development and commercialization of modified release products.

Prior to joining Alvogen in 2012, Dr. Joshi was Director Formulations (R&D) at Actavis, Senior Manager of Full Formulation Development at Apotext Inc, and Group Leader at Alembic, among other roles.

Dr. Joshi has a Ph.D. in Novel Drug Delivery Systems from the Maharaja Sayajirao University of Baroda. He has been named in numerous patents and published several scientific papers in respected journals around the world.